I was first drawn to medicine because I wanted to help people. I chose hematology and oncology because they are rapidly evolving fields—through their advances, I can treat people using the newest therapies. More importantly, I can care for people by forging meaningful relationships with them.
I treat each patient as a partner, and together, we work toward a common goal. Communication with my patients and their caregivers is essential to providing the best care. I also prioritize providing my patients with access to clinical trials.
At Perlmutter Cancer Center, my colleagues and I approach cancer treatment as a collaboration between specialties. We offer patients the most current clinical trials and we strive to provide as much support as possible for patients and families during such a difficult time.
My clinical and research interest is gastrointestinal cancers, with a focus on liver and biliary cancer, pancreatic cancer, and gastric cancer. Currently, I am studying whether radiation therapy in combination with immunotherapy is an effective treatment for pancreatic cancer.
Conditions and Treatments
- abdominal tumor
- anal cancer
- biliary cancer
- colon cancer
- colorectal cancer
- esophageal cancer
- gallbladder cancer
- gastrointestinal cancer
- liver cancer
- pancreatic cancer
- rectal cancer
- stomach cancer
This provider accepts the following insurance plans.
Blue Cross Blue Shield
- Empire BCBS
- Empire BCBS Top Tier
Centers Plan For Healthy Living
- Centers Plan for Healthy Living
- Emblem Select Care Exchange
- GHI HMO
- Hamaspik Choice Medicare DSNP
- Hotel Trades
Longevity Health Plan
- Longevity Health Plan Medicare
- Oxford Mosaic
- Railroad Medicare
River Spring Health Plan
- River Spring Medicare HMP SNP
Senior Whole Health
- Senior Whole Health
WTC Health Program
- WTC Health Program
- WellCare Medicare
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence.
Chinese clinical oncology. 2023 Aug ; 12(4):41
World journal of gastroenterology : WJG. 2023 Apr 21; 29(15):2261-2271
International journal of biological sciences. 2023 Mar ; 19(4):1009-1023